abt-199 and Arthritis--Rheumatoid

abt-199 has been researched along with Arthritis--Rheumatoid* in 1 studies

Other Studies

1 other study(ies) available for abt-199 and Arthritis--Rheumatoid

Article	Year
Discovery of JNJ-64264681: A Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase. Journal of medicinal chemistry, 2022, 11-10, Volume: 65, Issue:21 Bruton's tyrosine kinase (BTK) is a Tec family kinase that plays an essential role in B-cell receptor (BCR) signaling as well as Fcγ receptor signaling in leukocytes. Pharmacological inhibition of BTK has been shown to be effective in treating hematological malignancies and is hypothesized to provide an effective strategy for the treatment of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. We report the discovery and preclinical properties of JNJ-64264681 ( Topics: Agammaglobulinaemia Tyrosine Kinase; Arthritis, Rheumatoid; Autoimmune Diseases; Humans; Lupus Erythematosus, Systemic; Protein Kinase Inhibitors	2022

Article

Year

Discovery of JNJ-64264681: A Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.

Journal of medicinal chemistry, 2022, 11-10, Volume: 65, Issue:21

Bruton's tyrosine kinase (BTK) is a Tec family kinase that plays an essential role in B-cell receptor (BCR) signaling as well as Fcγ receptor signaling in leukocytes. Pharmacological inhibition of BTK has been shown to be effective in treating hematological malignancies and is hypothesized to provide an effective strategy for the treatment of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. We report the discovery and preclinical properties of JNJ-64264681 (

Topics: Agammaglobulinaemia Tyrosine Kinase; Arthritis, Rheumatoid; Autoimmune Diseases; Humans; Lupus Erythematosus, Systemic; Protein Kinase Inhibitors

2022